Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M-PLACE: MOR202 (Felzartamab) in Anti-PLA2R+ Membranous Nephropathy
NCT04145440Phase 2Completed
- Sponsor
- Biogen
- Start
- Oct 2019
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, open-label trial of felzartamab in membranous nephropathy (MN) (2 cohorts), sponsored by Biogen. Primary endpoint: Number and Percentage of Participants With Adverse Events. Started Oct 2019; status: completed.
02
Drugs
felzartamab
03
Conditions
membranous nephropathy (MN)
Beyond the preview
Go deeper on NCT04145440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04145440.